Skip to main content
Pharmaron Beijing Co., Ltd logo

Pharmaron Beijing Co., Ltd — Investor Relations & Filings

Ticker · 3759 ISIN · CNE100003PG4 HKEX Professional, scientific and technical activities
Open in API
Filings indexed 988 across all filing types
Latest filing 2025-10-28 Board/Management Inform…
Country HK Hong Kong
Listing HKEX 3759

About Pharmaron Beijing Co., Ltd

http://www.pharmaron.com

Pharmaron is a premier life science service provider and a comprehensive Contract Research and Manufacturing Organization (CRO/CDMO). The company delivers integrated research, development, and manufacturing capabilities across the entire drug development continuum, encompassing discovery, preclinical testing, clinical trials, and commercialization. Pharmaron's service portfolio supports diverse modalities, including small molecules, biologics, and advanced therapeutics such as cell and gene therapy (CGT) products. It partners with pharmaceutical, biotechnology, and medical device companies globally to advance their R&D pipelines.

Recent filings

Filing Released Lang Actions
(1) RESIGNATION AND CESSATION OF OFFICE OF INDEPENDENT NON-EXECUTIVE DIRECTOR&#x3b; (2) NOMINATION AND PROPOSED BY-ELECTION OF INDEPENDENT NON-EXECUTIVE DIRECTOR OF THE THIRD SESSION OF THE BOARD&#x3b
Board/Management Information Classification · 85% confidence The document is an official announcement by a listed company regarding the resignation of an independent non-executive director, the nomination and proposed by-election of a new independent non-executive director, and proposed amendments to the company’s Articles of Association. It does not contain financial results, audit opinions, or dividend notices, but rather focuses on board composition and corporate governance changes. This clearly falls under “Board/Management Information” as it announces changes in the board of directors.
2025-10-28 English
ACQUISITION OF 82.54% INTEREST IN BIORTUS CONSTITUTING CONNECTED TRANSACTION
M&A Activity Classification · 88% confidence The document is a formal stock exchange announcement by Pharmaron Beijing Co., Ltd. regarding the acquisition of an 82.54% interest in Biortus. It details the transaction terms, parties, consideration, conditions precedent and Listing Rules implications, fitting squarely into M&A activity. It is neither a full annual/interim report, nor an earnings release, but an acquisition announcement constituting a connected transaction under HKEX Listing Rules Chapter 14A. Therefore, it should be classified as M&A Activity (TAR).
2025-10-28 English
2025 THIRD QUARTERLY REPORT
Interim / Quarterly Report Classification · 100% confidence The document is titled '2025 THIRD QUARTERLY REPORT' for Pharmaron Beijing Co., Ltd. It contains detailed financial statements, including major accounting data, financial indicators, revenue breakdowns by service and region, and analysis of changes in financial items. It is a comprehensive quarterly financial report, not an announcement of a report or a summary, and it contains substantive financial data. 9M 2025
2025-10-28 English
NOTICE OF BOARD MEETING
Regulatory Filings Classification · 72% confidence The document is a formal stock exchange announcement notifying investors of a future Board of Directors meeting to approve third quarterly results. It contains no materials from an AGM, no executive changes, no financial figures themselves, and is not the actual quarterly report. It does not announce a change in board membership (MANG), nor does it publish or attach a report (RPA). Therefore it is a general regulatory filing (RNS) for Hong Kong Exchange disclosure.
2025-10-14 English
An announcement has just been published by the issuer in the Chinese section of this website, a corresponding version of which may or may not be published in this section
Regulatory Filings Classification · 95% confidence The document is extremely short (242 characters) and serves as a notification that an announcement has been published elsewhere on the website. It does not contain financial data, meeting details, or specific corporate actions, but rather acts as a pointer to another document. Per the 'Menu vs Meal' rule, this is a Report Publication Announcement.
2025-10-09 English
Monthly Return of Equity Issuer on Movements in Securities for the month ended 30 September 2025
Regulatory Filings Classification · 85% confidence The document is an HKEX FF301 monthly return for movements in share capital, issued and treasury shares, submitted under Chapter 19B of the Exchange Listing Rules. It is a routine regulatory filing to the stock exchange, not an earnings release, report, or announcement of a specific corporate action. Therefore, it falls under the general regulatory filings category.
2025-10-08 English

Browse filings by year

8 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.